Key findings of the study are as follows: 76 of 145 410 patients (incidence rate 1.33 events per 10 000 person years) treated with GLP1 receptor agonists and 184 of 291 667 patients (incidence rate 1.46 events per 10 000 person years) treated with DPP4 inhibitors developed thyroid cancer
Results guide personalised nutrition, supplements, and lifestyle adjustmentssuch as probiotics or dietary changesto strengthen gut resilience, reduce digestive discomfort, and promote long-term wellbeing
Patients lose up to 1520% of their body weight
While some of these studies showed that the addition of GLP-1 therapies to insulin led to improvements in HbA1c, total insulin dose, and weight, the benefits were relatively modest and accompanied by some side effects like hypoglycemia (low blood sugar)
Wet age-related macular degeneration A recent study published in June found that patients with type 2 diabetes who took GLP-1s were more than twice as likely to develop wet AMD as those who did not